पैर और टखने पर नैदानिक ​​अनुसंधान

अमूर्त

Bioburden vs. Antibiogram of Diabetic Foot Infection

Janifer Jasmine, Geethalakshmi Sekkizhar, Satyavani Kumpatla and Vijay Viswanathan

Background: Proper management of diabetic foot infection requires appropriate selection of antimicrobials based on culture and antimicrobial susceptibility testing. The aim was to determine the optimal antimicrobial susceptibility to various commonly used antimicrobials for Gram Positive Cocci (GPCs) and Gram Negative Bacilli (GNBs) in patients with type 2 diabetes and foot infection and also to find out the percentage of MRSA (Methicillin Resistant Staphylococcus aureus) and ESBL (Extended Spectrum of Beta-Lactamase)-producing pathogens and their susceptibility pattern.

Materials and methods: A total of 961 (M: F 697: 264) patients with type 2 diabetes and foot infection were included in this study. After surgical debridement, pus and tissue samples were collected under aseptic conditions in sterile containers and subjected to microbiological analyses. Gram’s staining, culture and sensitivity test were done along with quality control procedures.

Results: Among 961 subjects, single pathogens were isolated in 65.3%, poly-microbial organisms were isolated from 14.3% and 20.4% had sterile cultures. A total of 892 pathogens were isolated, of which 41.1% were GPCs, 57.7% were GNBs and 1.1% were Candida Spp. Imipenem showed the highest sensitivity of more than 95% and Amikacin above 70% against both GPCs and GNBs. Beta-lactam/beta-lactamase inhibitors showed more than 60% sensitivity to GNBs. GPCs were also >75% susceptible to doxycycline, 99.4% sensitive to vancomycin, 89.1% to linezolid, >55% to clindamycin and erythromycin. 1.35% of MRSA and 3.12% of ESBL were isolated from foot ulcers.

Conclusions: In conclusion, Imipenem was found to be the most potential antimicrobial against both GPCs, and GNBs. Among the combinations, cefipime-tazobactum and cefoperazone-sulbactum was the best choice. Anti-MRSA antimicrobials, linezolid and vancomycin and Anti-ESBLs like Imipenem and meropenem can be given to patients producing MRSA or ESBL.